



Jacobson Pharma Updates on TAILORx¹ Study

* * * *

Landmark TAILORx Results, Published in *The New England Journal of Medicine*, Demonstrate the Oncotype DX Breast Recurrence Score[®] Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving

(Hong Kong, 13 June 2018) **Jacobson Pharma Corporation Limited** (“**Jacobson Pharma**” or the “**Group**”; **Stock Code: 2633**), the Hong Kong and Macau exclusive distributor of **Genomic Health, Inc. (NASDAQ: GHDX)**, the world’s leading provider of genomic-based diagnostic tests, is pleased to share that the Trial Assigning Individualized Options for Treatment (Rx), or TAILORx, successfully defined the benefit of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score[®] results of 11 to 25. The long-awaited results of the TAILORx study, the largest ever breast cancer treatment trial, sponsored by the National Cancer Institute (NCI), and led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), provided definitive evidence that the Oncotype DX Breast Recurrence Score test identified 70 per cent of early-stage breast cancer patients who received no benefit from chemotherapy, and can be effectively treated with endocrine therapy alone. Additionally, the trial established that chemotherapy may provide life-saving benefit to 30 per cent of patients.

The TAILORx results were published on June 3rd in *The New England Journal of Medicine* in conjunction with a presentation during the Plenary Session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, United States.

The Oncotype DX[®] gene expression tests carried out by Genomic Health have been used to guide treatment decisions for more than 900,000 cancer patients in more than 90 countries. The Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment.

Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, said, “Breast cancer is one of the most common types of cancerous disease with about 4,000² new cases found in Hong Kong, as well as about 270,000³ new cases in China. . Jacobson has been the exclusive distributor of Genomic Health in Hong Kong and Macau for 10 years. We are confident that with our close collaboration with Genomic Health and our in-depth experiences in the relevant markets, we are well positioned to continue expanding business opportunities emerging in this arena.”

– End –

¹ Trial Assigning Individualized Options for Treatment(Rx) (To read the article, please visit: <https://www.nejm.org/doi/full/10.1056/NEJMoa1804710>)

² Source: Hong Kong Cancer Registry

³ Source: Report of Incidence and Mortality from China Cancer Registries

About Jacobson Pharma Corporation Limited (雅各臣科研製藥有限公司 ; Stock Code: 2633)

Jacobson Pharma is the largest generic drug company in Hong Kong with over 30% share of the total generic drug market for each year since 2012. The Group's proprietary medicines, notably being Po Chai Pills (「保濟丸」), Tong Tai Chung Woodlok Oil (「唐太宗活絡油」), Ho Chai Kung Tji Thung San (「何濟公正痛退熱散」), Contractubex Scar Gel (「秀碧除疤膏」) Doan's Ointment (「兜安氏藥膏」), Flying Eagle Wood Lok Medicated Oil (「飛鷹活絡油」), Saplingtan (「十靈丹」), Shiling Oil (「十靈油」) and Col-gan Tablet (「傷風克」) have been widely recognized by the market. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: <http://www.jacobsonpharma.com>

For media enquiries, please contact:

Strategic Financial Relations Limited

Vicky Lee	Tel: (852) 2864 4834	Email: vicky.lee@sprg.com.hk
Stephanie Liu	Tel: (852) 2864 4852	Email: stephanie.liu@sprg.com.hk
Queenie Chan	Tel: (852) 2864 4851	Email: queenie.chan@sprg.com.hk
Fax: (852) 2527 1196		